Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma.
Cyclophosphamide
Mobilization
Multiple myeloma
Journal
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
ISSN: 1473-0502
Titre abrégé: Transfus Apher Sci
Pays: England
ID NLM: 101095653
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
28
04
2020
revised:
26
05
2020
accepted:
31
05
2020
pubmed:
27
6
2020
medline:
7
8
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
Autologous stem cell transplantation (ASCT), supported by high-dose chemotherapy, is the prevalent option for multiple myeloma (MM) treatment in candidates suitable for transplantation. Although granulocyte colony-stimulating factor (G-CSF) supported cyclophosphamide (CY) is used as the pre-ASCT mobilization regimen, there is no consensus on the optimal dosage of CY. Thus, in this study, we examined the results of 47 MM patients, who underwent ASCT after mobilization with intermediate (ID) or low-dose (LD) CY treatment supported with G-CSF. As the mobilization regimen, we used ID (2.4 g/m
Identifiants
pubmed: 32586769
pii: S1473-0502(20)30147-6
doi: 10.1016/j.transci.2020.102844
pii:
doi:
Substances chimiques
Granulocyte Colony-Stimulating Factor
143011-72-7
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Langues
eng
Pagination
102844Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.